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Abstract
Systemic lupus erythematosus is a systemic autoimmune disease
characterized by the production of antinuclear antibodies (ANAs).
Recent research into human and murine lupus suggests that
disease susceptibility results from genetic polymorphisms regula-
ting immune responses as well as impairing the clearance of apop-
totic cells. Because the products of dead cells, including nucleic
acids, have immunologic activity, this situation can promote antigen-
driven ANA responses. Furthermore, immune complexes of ANAs
can drive the production of proinflammatory cytokines, inducing the
‘interferon signature’, and intensifying disease. Together, these
findings point to new genetic and immunologic markers of disease
as well as targets for new therapies.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic auto-
immune disease that is characterized by the production of
antibodies to nuclear molecules in association with clinical
manifestations of fluctuating intensity and severity. This
disease primarily affects young women and occurs with
variable frequency in racial and ethnic groups. Furthermore,
although SLE has a strong genetic component, its occur-
rence is sporadic in families and concordance is incomplete,
even among identical twins. Together, these observations
have suggested that the etiology of SLE has genetic and
environmental components, with female sex strongly influen-
cing pathogenesis.
Consistent with the systemic nature of SLE, the clinical
manifestations of this disease are diverse, with the skin,
joints, kidneys, nervous system, serosal surfaces, and blood
elements prominently involved. These manifestations occur to
a variable extent in the individual patient and their activity can
change over time. Although lupus is classically a disease of
flares, in some patients sustained remission can occur after
an initial phase of activity; in other patients the disease is
more sustained. The challenge in understanding SLE is
therefore to explain the heterogeneity in disease course and
to develop a model of pathogenesis that encompasses
disparate clinical events.
During the past decade studies of the immune system in
patients and animal models have provided important new
insights into underlying disease mechanisms and have led to
an encompassing model of pathogenesis in which antinuclear
antibodies (ANAs) play a central role in promoting immune
dysregulation and tissue injury. This model (Figure 1)
incorporates an aberrant immune response to cell death in
lupus, with immune complexes comprised of ANAs and the
products of dead cells activating the innate immune system
and driving inflammation and autoantibody production. This
review considers new data on pathogenesis and highlights
opportunities to develop new therapies.
Etiology of systemic lupus erythematosus
Genetic analysis of SLE has advanced impressively, reflect-
ing the powerful analytic tools created by the Human
Genome Project. Importantly, a combination of genome-wide
scanning, family studies, and candidate gene approaches has
led to identification of a series of genes that determine either
susceptibility to disease or its severity (Table 1). Although it is
likely that many more genes contribute to pathogenesis, the
nature of genes thus far identified suggests that patients with
SLE have an immune system predisposed to aberrant res-
ponsiveness. These patients may also have genetic variants
that may affect the interactions among immune cells to
enhance inflammation or promote vascular damage [1,2].
The study of human lupus has been complemented by a
detailed analysis of the genetics of murine lupus. Through
large and detailed breeding studies, investigators have
dissected the gene loci that contribute to disease in mice of
several strain backgrounds. These studies indicated clearly
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that, in inbred mice, disease is multigenic and loci can
promote as well as retard disease. Furthermore, whereas a
single gene locus may, for example, disturb B-cell activation,
additional gene or genes must be present for a full-blown
autoimmune syndrome. Another finding to emerge from this
analysis concerns the linkage, in the same chromosomal
location, of more than one susceptibility gene [3,4].
In addition to the role played by genetic polymorphisms in
disease susceptibility, epigenetic modifications to DNA may
influence risk. Such epigenetic factors include DNA methy-
lation and post-translational modifications of histones, which
can be either inherited or environmentally modified. Recent
studies have indicated global hypomethylation in the T cells
of patients with SLE. Furthermore, in mice drugs such as
procainamide and hydralazine can promote lymphocyte
hypomethylation to induce lupus [5].
Although these genetic and epigenetic factors may promote
susceptibility to SLE, environmental influences probably trigger
the start of autoimmunity. Among these infections, Ebstein-Barr
virus may promote lupus, given its extensive immune effects.
Furthermore, constituent proteins of the virus resemble self-
antigens and may, in genetically predisposed individuals, drive
autoantibody responses by molecular mimicry [6].
Serological abnormalities in systemic lupus
erythematosus
The production of antibodies to the cell nucleus (ANAs) is the
serologic hallmark of SLE. Of these antibodies, anti-DNA
antibodies serve as markers for diagnosis and prognosis and
occur in both patients and animal models of SLE. Indeed, in
animals, anti-DNA expression is the defining immunologic
feature of this disease. In addition to their expression of anti-
DNA, patients with SLE express other ANAs in a pattern that
has been characterized as linkage. Thus, anti-DNA antibodies
occur in association with antibodies to histones as well as
histone-DNA complexes that comprise the nucleosome.
Similarly, antibodies to Sm and RNP occur together
frequently. Sm and RNP are ribonucleoprotein complexes that
reside in the cell nucleus and mediate RNA processing [7,8].
Although both anti-DNA and anti-Sm are serologic criteria for
classification, the expression of antibodies to nucleosomes
and antibodies to RNP and Sm are independent. Whereas
levels of anti-DNA vary with disease activity, anti-Sm and anti-
RNP exhibit much less variation over time and have not been
clearly associated with disease activity or response to
therapy. The independence of these responses implies the
existence of more than one pathway for autoreactivity as well
as sources of autoantigen to drive autoantibody production
[8]. Furthermore, in patients with SLE, autoantibody expres-
sion can predate clinical disease manifestations by many
years, suggesting that for full-blown disease to develop other
events must supervene to translate serologic abnormalities
into active autoimmunity [9].
The generation of autoantibodies
A major question in the pathogenesis of SLE concerns the
basis for autoantibody specificity. Whereas ANA production
Figure 1
Model of key events in SLE pathogenesis. Dying cells release nucleic acid, including DNA, which binds immunoglobulin to form circulating immune
complexes. These immune complexes can directly mediate cell damage by binding to target tissues, for example in the glomerulus. Immune
complexes also bind Fc receptors on plasmacytoid dendritic cells, and in concert with RAGE receptors and TLR9, promote expression and release
of IFN-α. IFN-α, in turn, promotes multiple immune system aberrations including the upregulation of B cells, T cells, and dendritic and endothelial
cells. RAGE, receptor for advanced glycation end-products; SLE, systemic lupus erythematosus; TLR, Toll-like receptor.Page 3 of 8
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is common to many rheumatic diseases, the targeting of
nucleic acids is a striking feature of autoimmunity in SLE.
Recent research has identified possible explanations for this
targeting that converge on the ability of certain self-molecules
to stimulate immune responses, a concept known as danger.
Stated simply, danger represents an immunologic challenge
that activates the innate immune system and stimulates host
defense. In the susceptible person, danger may also trigger
autoimmunity.
Danger can arise from both exogenous and endogenous
sources. Exogenous sources include foreign molecules
known as pathogen-associated molecular patterns (PAMPs)
such as endotoxin (lipopolysaccharide) and bacterial, viral,
and fungal molecules. The endogenous danger molecules are
called death (or damage)-associated molecular patterns
(DAMPs). DAMP can arise during tissue injury or death and
are self-molecules that acquire immunologic activity when
they are either degraded or released from their normal intra-
cellular location [10].
Among PAMPs and DAMPs, DNA and RNA exhibit important
immunological activity. Double-stranded RNA from viruses
can stimulate Toll-like receptor (TLR)3; single-stranded RNA
can stimulate TLR7; and DNA from bacterial sources
enriched with CpG motifs (so-called CpG DNA) can
stimulate TLR9. Furthermore, although mammalian DNA itself
may be immunologically inactive (because of a paucity of
CpG motifs), it can nevertheless stimulate cells when it is
introduced into the cytoplasm by alternative pathways such
as transfection or DNA-binding proteins [11,12]. Within the
context of SLE, these findings suggest that molecules
inducing autoimmunity have intrinsic immunologic activity and
may serve as adjuvants for their own responses as well those
to molecules to which they are attached [13].
A second explanation for the targeting of nuclear molecules in
SLE relates to an increase in the exposure of the immune
system in lupus to ‘dangerous’ products. This increase could
result from either an increase in the amount of cell death or a
failure to clear the products of dead and dying cells. In the
simplest conceptualization, cells can die by apoptosis or
necrosis. Apoptosis is a form of programmed cell death in
which macromolecules are degraded or translocated by
enzyme cascades. Among these changes is the migration of
nuclear antigens into surface blebs. In contrast, necrosis is an
immediate or accidental form of cell death that is mediated by
physical or chemical trauma that culminates in the extra-
cellular dispersal of the contents. Importantly, many cellular
and humoral systems mediate the clearance of apoptotic
cells, presumably to prevent transition to secondary necrosis,
which appears to be a much more proinflammatory or
immunogenic state [14].
Measurement of the extent of in vivo apoptosis is difficult
because of uncertainty in sampling, although it is likely that
patients with SLE have increased apoptosis of peripheral
blood lymphocytes. In contrast, there is strong evidence from
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Table 1
Genes proposed to influence SLE risk [1,2]
Candidate gene Chromosomal location Proposed function
PTPN22 1p13 T cell activation
FCGR-2A, FCGR-2B, FCGR-3A, FCGR-3B 1q23-25 Fc receptors; clearance of immune complexes
TNFSF-4 1p36 TNFα expression
STAT-4 2q32 T cell cytokine production and macrophage response to IFN-α
CTLA-4 2q33 T cell activation
PDCD-1 2q37 Lymphocyte differentiation
PXK 3p14 Unknown
HLA-DR2, HLA-DR3 6p11-p21 Antigen presentation
IRF-5 7q32 Expression of IFN-α
BLK-C8orf13 8p23 B cell development and function
MBL-2 10q11 Antigen presentation and immune complex clearance
KIAA1542 11p15 Interferon alpha expression?
ITGAM 16p11 Adherence of neutrophils and monocytes to endothelium
BLK = B lymphocyte tyrosine kinase; CTLA = cytotoxic T-lymphocyte associated; FCGR = Fc gamma receptor; HLA = human leukocyte antigen;
IFN = interferon; IRF = interferon regulatory factor; ITGAM = integrin alpha(M); MBL = mannose binding lectin; PDCD = programmed cell death;
PTPN = protein tyrosine phosphatase nonreceptor; SLE = systemic lupus erythematosus; STAT = signal transducer and activator of transcription;
TNF = tumor necrosis factor; TNFSF = tumor necrosis factor ligand superfamily.both patients as well as animal models for aberrant clearance
of dead cells. Genetic deficiency of C1q, for example, is
highly associated with SLE. Because complement can
promote removal of dead cells, a deficiency in this system
can allow the accumulation of dead cells to drive the innate
immune system and serve as immunogen to induce ANAs. Of
note, blebs can also bind complement, with a complement
deficiency allowing these structures to escape into the
periphery to induce responses as well as promote immune
system and vascular changes. Similar considerations pertain
to the role played by other proteins such as C-reactive
protein and IgM, where deficiency may lead to impaired
clearance and enhanced autoreactivty [15].
Taken together, these considerations suggest that the induction
of ANAs results from aberrant production or accumulation of
danger molecules from dead cells, with the changes in these
molecules during apoptosis enhancing immunogenicity.
Furthermore, because cell death probably leads to the release
of other immune mediators known as alarmins, the immune
environment is replete with danger molecules that can promote
immune hyperactivity and autoreactivity.
Immunological abnormalities
In the pathogenesis of SLE, an increase in the amount of self-
antigen may not be sufficient to drive autoimmunity. Rather,
intrinsic abnormalities in cells of the adaptive immune system
(for example, B cells, T cells, and dendritic cells) may act
synergistically to induce a mature, antigen-driven response.
As shown in studies on both patients as well as animal
models, SLE is associated with functional disturbances that
involve the entirety of the immune system. Some of these may
be genetically determined, whereas others arise secondarily
in response to events such as infection. Not surprisingly,
delineation of these disturbances has evolved with the
development of new analytic approaches to elucidate the
immune cell function and the downstream signaling pathways
engaged during activation.
In peripheral blood of patients, both the B-cell and T-cell
compartments exhibit functional abnormalities that could lead
to the autoantibody production. Thus, among B-cell precursor
populations, there is a striking shift toward autoreactivity as
indicated by the binding specificity of antibody products. This
shift, which could predispose to ANA generation, reflects
impairment in B-cell tolerance. With a preimmune repertoire
filled with autoreactive precursors, drive by autoantigen may
more readily elicit a specific response [16].
Analysis of B-cell populations during disease also reveals
distinctive abnormalities, including a prominent increase in
plasma cells during active disease. These cells can be enu-
merated by flow cytometry on the basis of their expression of
high levels of CD27. These changes are dynamic, however,
and can respond to immunosuppressive therapy [17,18].
Although the peripheral blood has been studied in detail, few
studies have characterized other B-cell compartments. Of
note, an analysis of germinal centers in the tonsils of normal
patients and patients with SLE revealed marked differences
in the expression of an idiotypic marker that is ordinarily not
expressed during tolerance induction [19]. Among influences
that affect B-cell activation or differentiation, cytokines such
as B-lymphocyte stimulator (BlyS) may promote these
functional and phenotypic changes [20].
As shown in studies of patients as well as animal models,
T cells in SLE exhibit abundant functional and phenotypic
abnormalities, with the role of T-helper cells in disease
suggested by the effectiveness of anti-T-cell approaches (for
instance, antibodies as well as genetic knockouts) in animal
models. In patients, these abnormalities can be defined by
analysis of cell phenotype as well as signal transduction
pathways. Thus, SLE patients exhibit evidence of increased
numbers of memory T cells as well as decreases in the
number or function of T-regulatory (Treg) cells. Among the
cells with the highest level of CD25 expression (a marker for
Treg cells) in vitro function is reduced, although this level can
be restored by activation, implying that a dynamic process is
at work [21,22]. Interactions of Treg cells with IFN-producing
antigen-presenting cells may also impair their function [23].
An important issue concerning the role of T-helper cells for
autoantibody production relates to their antigen specificity.
Among antigens targeted, DNA and RNA, in their ‘naked’
form, do not appear able to bind to the T-cell receptor.
Rather, in SLE, T-cell help for anti-DNA and other anti-nuclear
responses may result from recognition of nucleosomes, with
histone peptides serving as major autoepitopes to activate
T cells and provide help for autoantibody production [24].
Because nucleosomes can arise during nuclear breakdown in
apoptosis, cell death may also directly impact on T-cell
autoreactivity. The induction of autoreactive T cells may be
promoted during disease, because - at the molecular level -
SLE T cells exhibit evidence of ‘rewiring’ and increased
activation of the T-cell receptor transduction system [24,25].
Cytokine disturbances in systemic lupus
erythematosus: the role played by immune
complexes
Microarray and other molecular approaches have provided a
new dimension to the analysis of immune cell function in SLE
and provided dramatic evidence for cytokine disturbance.
Thus, as shown by studies conducted by several investi-
gators, peripheral blood mononuclear cells from patients with
SLE exhibit patterns of gene expression consistent with in
vivo stimulation by type 1 IFN. Although not all patients have
this ‘interferon signature’, it nevertheless represents clear
evidence of the effects of cytokines on the immune system in
SLE [26-28]. The potential effects of IFN in lupus are
widespread, because overproduction of this cytokine can
promote expression of proinflammatory cytokines and
chemokines, maturation of monocytes into dendritic cells,
Arthritis Research & Therapy    Vol 10 No 5 Ardoin and Pisetsky
Page 4 of 8
(page number not for citation purposes)activation of autoreactive B and T cells, production of auto-
antibodies, and loss of self-tolerance. Furthermore, IFN may
adversely affect the vasculature by inducing endothelial
dysfunction and depleting endothelial progenitor cells for
repair. Studies conducted in animals support the critical role
of IFN, because lupus mice that are deficient in type I IFN
receptors have significantly reduced disease expression [29].
Although lupus nephritis has long been conceptualized as a
classic immune complex disease, studies conducted in both
human and murine systems have revolutionized the concept
of immune complexes and have demonstrated convincingly
that immune complexes can promote aberrant cytokine
production, serving as potent inducers of IFN-α. Thus, as
shown originally in in vitro culture systems, the blood of SLE
patients contains a factor that can induce the production of
IFN-α by IFN-producing cells, also called plasmacytoid
dendritic cells. Original studies indicated that this factor
represents immune complexes comprised of DNA and anti-
DNA. Subsequent studies indicate that complexes can be
assembled by mixing patient sera with the media from
apoptotic cells and that antibodies to RNA binding proteins
could also form immunostimulatory complexes [30,31].
The stimulation of plasmacytoid dendritic cells by immune
complexes involves both TLR and non-TLR receptors, which
probably respond to the nucleic acid components of the
complexes. Because complexes may promote uptake into
cells, the nucleic acid component may have access to other
internal nucleic acid sensors, thereby eliminating the
requirement for CpG motifs. In addition to the role played by
pattern recognition receptors, stimulation of IFN production
by complexes involves the Fc receptors as well as RAGE
(receptor for advanced glycation end-products). The role
played by RAGE reflects the presence in the complexes of
high mobility group protein B1 (HMGB1). HMGB1, a
nonhistone nuclear protein, is a prototypic alarmin that is
released from apoptotic as well as necrotic cells. Because
HMGB1 binds to chromatin in the cell, its presence in the
complexes probably results from the release during cell death
of chromatin with its attached proteins [32-34].
Consistent with a role for nucleic acids in inducing IFN via
TLRs, inhibitory oligonucleotides can block the progression of
SLE in animal models [35,36]. The situation with respect to
effects of TLR knockouts is more complicated. Thus, in a
study of disease in autoimmune MRL/Mp-lpr/lpr  mice,
although a TLR7 knockout had reduced disease severity, a
TLR9 knockout had accelerated nephritis and increased
mortality. Furthermore, the effects of the knockouts on various
autoantibody responses differ, with TLR9 knockout mice
exhibiting reduced anti-nucleosome responses and TLR7
knockout mice showing reduced anti-Sm responses. These
findings indicate that the effects of activation via different
TLRs may differ, with the effects on IFN also varying
depending upon the TLR pathway stimulated [37].
Whatever the mechanism by which the immune complexes
stimulate responses, their formation requires the availability of
nuclear antigens in the extracellular milieu where antibody
binding may occur. Because media from apoptotic cells can
substitute for pure DNA in in vitro systems, cell death is the
probable setting for the release of nuclear material for
complex formation. The manner in which DNA and RNA leave
the cell has not been extensively investigated, although it
appears that both may be extruded from the cell during
apoptosis, albeit by separate mechanisms [38]. The
conditions for the conditions in which DNA and RNA exit the
cell may account for the differences in the pattern of
autoantibody product noted above.
Mechanism of organ damage in systemic
lupus erythematosus
Although the immune dysregulation inherent to SLE can
cause damage in nearly any organ system, the kidneys,
central nervous system, and endothelium remain major
sources of morbidity and mortality and have been studied
intensively over the past decade.
Kidney
Lupus nephritis results from glomerular deposition of immuno-
globulins, which in turn activate complement and promote
inflammation. As in the case of cytokine production, anti-DNA
antibodies play an important role in nephritis, with pathogenicity
resulting from either glomerular deposition of immune
complexes with nucleosomes or cross-reactive binding with
proteins (possibly α-actinin) in the glomerular basement
membrane. Although elevated anti-DNA levels may predict
lupus nephritis, not all SLE patients with circulating anti-DNA
antibodies exhibit this manifestation. These findings suggest
that only certain anti-DNA antibodies are nephritogenic or that
the presence of immune complexes, even when deposited in
the kidney, may not be sufficient to provoke glomerular injury.
As demonstrated most clearly in studies of mice, in addition
to immune complex formation, other mechanisms influence
immune cell recruitment to inflamed renal tissue. Thus, mice
that are deficient in the γ chain of the Fc receptor are
protected from the development of nephritis, despite the
presence of immune complex deposition and complement
activation. T cells may also be involved in this manifestation,
because, in mice, depletion of CD4+ cells and antagonism of
CD28/B7, CD40/CD40 ligand, and ICAM-1/LFA (inter-
cellular adhesion molecule-1/lymphocyte function-associated
antigen) co-stimulation attenuates nephritis [39].
In renal biopsies from SLE patients with class III and IV
glomerulonephritis, CD8+ T cells predominate in the
inflammatory infiltrate [40]. Although renal biopsies are
informative, their performance carries risk and repeat biopsies
are difficult. The urine itself may provide a new source of
material for assessing mechanisms of nephritis as well as
clinical disease activity. Thus, urine of patients with active
Available online http://arthritis-research.com/content/10/5/218
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markers. Assessment of levels of these products is a potential
marker of disease activity and prognosis [41].
The central nervous system
Neuropsychiatric SLE (NPSLE) is a clinical category that
comprises a multitude of syndromes whose mechanisms
probably vary significantly. At least some of these manifes-
tations, however, may result from the direct effects of anti-
bodies. Although a wide array of autoantibodies has been
described in the serum and cerebrospinal fluid of individuals
with NPSLE, studies in both human and murine lupus
highlight the potential the role played by antibodies to the N-
methyl-D-aspartate receptors NR2a and NR2b in the
cognitive dysfunction in SLE. These antibodies represent a
subset of antibodies to double-stranded DNA that cross-
react with the extracellular domain of NR2 receptors. These
receptors occur throughout the brain and are key to learning,
memory, and pathogenesis of psychosis [42].
As shown in murine models, anti-NR2 glutamate receptor
antibodies can induce a noninflammatory, neurotoxic effect
on neurons, particularly in the hippocampus, resulting in
cognitive impairment. Importantly, disruption of the blood-
brain barrier is necessary for this effect. Despite the clarity of
the murine models, studies in SLE patients have yielded more
mixed results, with only some showing correlations between
the presence of anti-NR2 antibody and cognitive impairment.
Because most of these clinical studies have assessed serum
and not cerebrospinal fluid levels of the anti-NR2 antibodies,
it is uncertain whether in patients a breach in the blood-brain
barrier (a crucial factor in the animal models) has occurred to
allow antibody penetration into the brain [43].
Among other autoantibodies, antiphospholipid antibodies
promote the pathogenesis of focal ischemic disease in SLE
and may also mediate more diffuse cognitive impairment [43].
More controversial in the etiology of NSPLE is the role played
by anti-ribosomal P antibodies, which target three different
ribosomal proteins. These antibodies were originally
described in conjunction with psychosis and depression in
SLE, but more recent reports have provided less clear asso-
ciations [44]. Of interest, it has been demonstrated in a
murine model that the intracerebral administration of human
anti-ribosomal P can induce depressive behavior, with stain-
ing of antibody to various neuronal populations [45].
In addition to autoantibodies, cytokines and chemokines
probably contribute to the pathogenesis of NPSLE and cog-
nitive dysfunction. Among these mediators, interleukin-6,
interleukin-8, CCL5 (C-C chemokine ligand 5, or RANTES),
CX3CL1 (C-X3-C chemokine ligand 1, or fractalkine), mono-
cyte chemotactic protein-1, and CXCL9 (C-X-C chemokine
ligand 9, or MIG) are increased in the cerebrospinal fluid of
patients with active NPSLE and may mediate events that
promote neuronal damage or dysfunction [46,47].
Vasculature
Complications of SLE include vasculitis and atherosclerosis,
reflecting the major impact of the immune system on the
endothelium. In the atherosclerosis associated with SLE,
traditional cardiovascular risk factors and medications do not
fully account for the strikingly increased risk of athero-
sclerosis seen in premenopausal women with SLE. These
findings suggest that features of the disease itself drive this
process. Even in the absence of clinical atherosclerosis and
overt disease activity, patients with SLE show evidence of
impaired endothelial function [48].
Several distinct mechanisms probably promote endothelial
injury on SLE. Thus, endothelial damage may result from
immunologic factors that include immune complex deposition,
complement activation, and direct cell-mediated cytotoxicity
to the endothelium. In addition, antibodies to phospholipids,
endothelial cells, and oxidized low-density lipoprotein may
exert pathogenic effects. Acting together, these mechanisms
may increase endothelial cell apoptosis, diminish production
of endothelial-derived nitric oxide, and increase endothelial
exposure of procoagulant tissue factor and phosphatidyl-
serine. In addition, enhanced IFN levels may increase endo-
thelial cell apoptosis and promote abnormal vasculogenesis.
In the face of these insults, the endothelium of SLE patients
may have limited capacity for repair, because monocyte
(CD14+) and hematopoietic stem-cell derived (CD34+ and
CD133+) endothelial progenitor cells, usually recruited to
restore damaged endothelium, are diminished in number and
function in SLE [49,50].
Conclusion
Recent discoveries concerning immune abnormalities in SLE
have provided the scientific basis for more targeted treatment
that may interdict key steps in the pathogenesis. Agents
currently under trial or for which trials are planned based on
promising results in animal models include anti-B-cell therapy
(anti-CD20 and anti-CD22); CTLA-4Ig (cyctotoxic T-lympho-
cyte associated antigen 4/immunoglobulin), which impairs
T cell co-stimulation; anti-cytokine approaches directed
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A Decade of Progressagainst BlyS, interleukin-10, tumor necrosis factor-α, and IFN-α;
and TLR inhibition [51]. In addition to exploring novel
therapies in SLE, recent research efforts have provided
insights into the action of older agents such as hydroxy-
chloroquine, which may be immunomodulatory because of
effects on TLR9 signaling [52]. Coupled with potential new
markers (for example, IFN signature and fluorescence-
activated cell sorting analysis of B-cell populations), the new
era of trials in SLE should refine our understanding of disease
pathogenesis and hopefully provide a new generation of more
effective and less toxic targeted therapies.
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